BOSTON SCIENTIFIC CORP (BSX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-05

Key Insights

Boston Scientific successfully eliminated supermajority voting provisions in its charter, reducing barriers to future takeover attempts and enhancing shareholder voting power with 98.6% approval on the amendment.
The company added officer exculpation provisions under Delaware law, which provides legal protection for officers in certain circumstances but received notably lower shareholder support (87.5% approval) compared to other governance items.
All 10 board directors were re-elected with strong support, though David Habiger and Cathy Smith received lower vote percentages (85.9% and 92.6% respectively) compared to other nominees, potentially signaling selective investor concerns.
Stockholders decisively rejected both proposals regarding special meeting rights (shareholders owning 25% stock), with the stockholder proposal receiving only 42.8% support, indicating investor preference for maintaining existing governance controls.
The company expanded its Employee Stock Purchase Plan with overwhelming approval (99.8%), suggesting management confidence in employee engagement and stock-based compensation strategy.

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-22

Boston Scientific announced Q1 2026 financial results on April 22, 2026, providing investors with the first quarterly performance update of the year through the press release filed as Exhibit 99.1.
The filing confirms the company maintains dual securities listings on NYSE (common stock under ticker BSX and senior notes due 2027 under ticker BSX27), indicating active debt management alongside equity operations.
As a non-emerging growth company, Boston Scientific is subject to full SEC compliance requirements and SOX auditing standards, suggesting it is an established large-cap medical device manufacturer with significant market presence.

Filed: 2026-03-30

Boston Scientific announced positive results from two key clinical trials, HI-PEITHO and CHAMPION-AF, which could indicate potential product pipeline advancements and growth opportunities.
The company filed this 8-K to disclose the clinical trial results, suggesting these are material events that could impact the stock price.
Investors should monitor the progress of these trials and potential regulatory and commercial milestones that could arise from these developments.

Filed: 2026-02-26

Boston Scientific entered into a $3 billion revolving credit agreement that matures in 2031, providing the company with significant financial flexibility.
The agreement includes an option to extend the maturity by one year, subject to lender approval, indicating the company's ability to negotiate favorable terms.
The agreement allows Boston Scientific to exclude certain cash litigation payments from its financial covenants, potentially mitigating the impact of legal disputes on its leverage ratio.

Filed: 2026-02-23

Boston Scientific announced the appointment of two new directors, Catherine R. Smith and Christophe P. Weber, to its Board, effective February 18, 2026.
The Board also approved an increase of $4.0 billion to the company's existing stock repurchase program, bringing the total authorization to $5.0 billion.
The new directors will receive standard non-employee director compensation, including a cash retainer and equity award, prorated for the period until the 2026 annual meeting.

Filed: 2026-02-05

Boston Scientific announced that Yoshiaki Fujimori, a member of the Board of Directors since 2016, will not stand for re-election at the 2026 Annual Meeting.
The company stated that Fujimori's decision is not the result of any disagreement with the company, and the Board will evaluate whether to add new directors after his departure.
This change in Board composition could signal a shift in the company's strategic priorities or leadership, which investors should monitor for potential impacts.

Filed: 2026-02-04

Boston Scientific Corporation reported financial results for the fourth quarter and full year 2025, indicating the company's performance was in line with market expectations.
The company's senior notes due 2027 are publicly traded, providing investors with an additional fixed-income investment option from the medical device manufacturer.
The 8-K filing does not indicate any major leadership changes or material agreements that would significantly impact the company's operations or future outlook.

Filed: 2026-01-15

Boston Scientific is acquiring Penumbra, a medical device company, in a major transaction that is expected to provide strategic and financial benefits.
The acquisition expands Boston Scientific's product portfolio and market reach, aligning with its growth strategy.
Investors should monitor the integration process and the financial and operational impact of the acquisition on Boston Scientific's future performance.

Filed: 2026-01-15

Boston Scientific Corporation has entered into an agreement to acquire Penumbra, Inc., a medical device company, for a combination of cash and stock consideration.
The acquisition will expand Boston Scientific's portfolio of medical devices and provide access to Penumbra's innovative products and technologies.
The transaction is subject to customary closing conditions, including regulatory approvals and Penumbra shareholder approval.

Other reports for BOSTON SCIENTIFIC CORP

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.